Canton Strategic Holdings, Inc.
About
Issuer
- Entity type
- Corporation
- Jurisdiction
- Delaware
- Sector
- Biotech
- Headquarters
- Red Bank, NJ
- Street
- 34 Shrewsbury Ave.
- Zip
- 07701
Offering
- Total offering
- $1.7M
- Amount sold
- $1.7M
- First sale
- Jul 23, 2025
- Min investment
- $0
- Securities
- Equity
- Federal exemption
- Rule 506(b)
- Investors so far
- 13
How this filing compares
Ranked #29 of 47 Biotech filings in April 2026 by offering amount.
Median Biotech filing in April 2026: $3M. This offering is 0.6× the median.
Other New Jersey filings this week: AUGUREY VENTURES I - SERIES ANDURIL E, AUGUREY VENTURES III - SERIES ANDURIL E, AUGUREY VENTURES QP FUND - SERIES ANDURIL E, AUGUREY VENTURES V - SERIES ANDURIL E, Bergamot Music Fund I LP
Leadership
Mark Wendland — Executive Officer (also: Director)
Jacob Asbury — Executive Officer
Angela Radkowski — Executive Officer
Mark Toomey — Executive Officer
Vincent LoPriore — Director
Also named on: Hepion Pharmaceuticals, Inc.
Sireesh Appajosyula — Director
Also named on: Hepion Pharmaceuticals, Inc.
Clay Kahler — Director
Gary Stetz — Director
Also named on: Hepion Pharmaceuticals, Inc.
Jill Sommers — Director
William Wiley — Director
Filing details
Canton Strategic Holdings, Inc. filed a Form D with the SEC on April 15, 2026.